Wells Fargo resumed coverage of Nevro (NVRO) with an Equal Weight rating and $5 price target Wells believes Nevro is comfortable with consensus implying a return to year over year sales growth in the second half of 2025, though the firm does not see upside to Street estimates, the analyst tells investors in a research note. Easier y/y comps, lessened competitive trialing, AdaptivAI ramp, continued healthy growth in painful diabetic neuropathy, adding new sales territories, and Vyrsa ramping could support 2025 growth, the firm says.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score a data driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVRO: